Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Videos

NCCN Guidelines for Treating Metastatic Castration-Resistant Prostate Cancer: Biomarker-Selected Patients


Read the transcript

Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer (mCRPC) for biomarker-selected patients.

Dr Choudhury is a Senior Physician at Dana-Farber Cancer Institute, Co-Director of the Prostate Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center, and Assistant Professor of Medicine at Harvard Medical School. Dr Morgans is Medical Oncologist at the Dana-Farber Cancer Institute, where I'm also the Medical Director of the Survivorship Program.

Watch part 1, where Dr Choudhury and Dr Morgans discuss treatment modalities that have demonstrated survival benefit in mCRPC for genetically unselected patients.

Advertisement

Advertisement

Advertisement